Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma

NCT04855695 is registered in ClinicalTrials.gov with Austin I Kim as lead sponsor.

NCT NCT04855695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04855695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma
Lead sponsor
Austin I Kim
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 2, 2021
Completion date
December 31, 2027
Enrollment
72 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma, refractory lymphoma